A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Doxorubicin (Primary) ; Ifosfamide (Primary) ; Mesna (Primary) ; Olaratumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Aug 2019 Status changed from active, no longer recruiting to completed.
- 31 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2018 Planned End Date changed from 1 Nov 2019 to 8 Nov 2019.